Cargando…
SARS-CoV-2 Testing for Asymptomatic Patients with Cancer Prior and during Treatment: A Single Centre Experience
Patients with cancer are more vulnerable to severe COVID-19. As a result, routine SARS-CoV-2 testing of asymptomatic patients with cancer is recommended prior to treatment. However, there is limited evidence of its clinical usefulness. The objective of this study is to evaluate the value of routine...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903264/ https://www.ncbi.nlm.nih.gov/pubmed/33419159 http://dx.doi.org/10.3390/curroncol28010032 |
_version_ | 1783654698878763008 |
---|---|
author | Meti, Nicholas Tahmasebi, Houman Leahey, Angela Boudreau, Angela Thawer, Alia Stewart, Janice Reason, Paige Albright, Kirsty Leis, Jerome A. Katz, Kevin Cheung, Matthew C. Singh, Simron |
author_facet | Meti, Nicholas Tahmasebi, Houman Leahey, Angela Boudreau, Angela Thawer, Alia Stewart, Janice Reason, Paige Albright, Kirsty Leis, Jerome A. Katz, Kevin Cheung, Matthew C. Singh, Simron |
author_sort | Meti, Nicholas |
collection | PubMed |
description | Patients with cancer are more vulnerable to severe COVID-19. As a result, routine SARS-CoV-2 testing of asymptomatic patients with cancer is recommended prior to treatment. However, there is limited evidence of its clinical usefulness. The objective of this study is to evaluate the value of routine testing of asymptomatic patients with cancer. Asymptomatic patients with cancer attending Odette Cancer Centre (Toronto, ON, Canada) were tested for SARS-CoV-2 prior to and during treatment cycles. Results were compared to positivity rates of SARS-CoV-2 locally and provincially. All 890 asymptomatic patients tested negative. Positivity rates in the province were 1.5%, in hospital were 1.0%, and among OCC’s symptomatic cancer patients were 0% over the study period. Given our findings and the low SARS-CoV-2 community positivity rates, we recommend a dynamic testing model of asymptomatic patients that triggers testing during increasing community positivity rates of SARS-CoV-2. |
format | Online Article Text |
id | pubmed-7903264 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-79032642021-02-25 SARS-CoV-2 Testing for Asymptomatic Patients with Cancer Prior and during Treatment: A Single Centre Experience Meti, Nicholas Tahmasebi, Houman Leahey, Angela Boudreau, Angela Thawer, Alia Stewart, Janice Reason, Paige Albright, Kirsty Leis, Jerome A. Katz, Kevin Cheung, Matthew C. Singh, Simron Curr Oncol Communication Patients with cancer are more vulnerable to severe COVID-19. As a result, routine SARS-CoV-2 testing of asymptomatic patients with cancer is recommended prior to treatment. However, there is limited evidence of its clinical usefulness. The objective of this study is to evaluate the value of routine testing of asymptomatic patients with cancer. Asymptomatic patients with cancer attending Odette Cancer Centre (Toronto, ON, Canada) were tested for SARS-CoV-2 prior to and during treatment cycles. Results were compared to positivity rates of SARS-CoV-2 locally and provincially. All 890 asymptomatic patients tested negative. Positivity rates in the province were 1.5%, in hospital were 1.0%, and among OCC’s symptomatic cancer patients were 0% over the study period. Given our findings and the low SARS-CoV-2 community positivity rates, we recommend a dynamic testing model of asymptomatic patients that triggers testing during increasing community positivity rates of SARS-CoV-2. MDPI 2021-01-06 /pmc/articles/PMC7903264/ /pubmed/33419159 http://dx.doi.org/10.3390/curroncol28010032 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Communication Meti, Nicholas Tahmasebi, Houman Leahey, Angela Boudreau, Angela Thawer, Alia Stewart, Janice Reason, Paige Albright, Kirsty Leis, Jerome A. Katz, Kevin Cheung, Matthew C. Singh, Simron SARS-CoV-2 Testing for Asymptomatic Patients with Cancer Prior and during Treatment: A Single Centre Experience |
title | SARS-CoV-2 Testing for Asymptomatic Patients with Cancer Prior and during Treatment: A Single Centre Experience |
title_full | SARS-CoV-2 Testing for Asymptomatic Patients with Cancer Prior and during Treatment: A Single Centre Experience |
title_fullStr | SARS-CoV-2 Testing for Asymptomatic Patients with Cancer Prior and during Treatment: A Single Centre Experience |
title_full_unstemmed | SARS-CoV-2 Testing for Asymptomatic Patients with Cancer Prior and during Treatment: A Single Centre Experience |
title_short | SARS-CoV-2 Testing for Asymptomatic Patients with Cancer Prior and during Treatment: A Single Centre Experience |
title_sort | sars-cov-2 testing for asymptomatic patients with cancer prior and during treatment: a single centre experience |
topic | Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903264/ https://www.ncbi.nlm.nih.gov/pubmed/33419159 http://dx.doi.org/10.3390/curroncol28010032 |
work_keys_str_mv | AT metinicholas sarscov2testingforasymptomaticpatientswithcancerpriorandduringtreatmentasinglecentreexperience AT tahmasebihouman sarscov2testingforasymptomaticpatientswithcancerpriorandduringtreatmentasinglecentreexperience AT leaheyangela sarscov2testingforasymptomaticpatientswithcancerpriorandduringtreatmentasinglecentreexperience AT boudreauangela sarscov2testingforasymptomaticpatientswithcancerpriorandduringtreatmentasinglecentreexperience AT thaweralia sarscov2testingforasymptomaticpatientswithcancerpriorandduringtreatmentasinglecentreexperience AT stewartjanice sarscov2testingforasymptomaticpatientswithcancerpriorandduringtreatmentasinglecentreexperience AT reasonpaige sarscov2testingforasymptomaticpatientswithcancerpriorandduringtreatmentasinglecentreexperience AT albrightkirsty sarscov2testingforasymptomaticpatientswithcancerpriorandduringtreatmentasinglecentreexperience AT leisjeromea sarscov2testingforasymptomaticpatientswithcancerpriorandduringtreatmentasinglecentreexperience AT katzkevin sarscov2testingforasymptomaticpatientswithcancerpriorandduringtreatmentasinglecentreexperience AT cheungmatthewc sarscov2testingforasymptomaticpatientswithcancerpriorandduringtreatmentasinglecentreexperience AT singhsimron sarscov2testingforasymptomaticpatientswithcancerpriorandduringtreatmentasinglecentreexperience |